Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00898261|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : May 19, 2017
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at gene expression in tissue from patients with acute lymphoblastic leukemia enrolled in clinical trial ECOG-2993.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: microarray analysis Genetic: reverse transcriptase-polymerase chain reaction Other: flow cytometry|
- Identify genes involved in specific biologic processes or molecular functions that contribute to the mechanisms by which the BCR/ABL tyrosine kinase induces a leukemic phenotype using RNA banked from patients with BCR/ABL-positive acute lymphoblastic leukemia (ALL) enrolled on ECOG-2993.
- Compare patterns of mRNA expression of BCR/ABL fusion protein in patients with B-lineage ALL vs patients with ALL and no cytogenetic abnormalities enrolled on ECOG-2993.
- Determine both shared and differing expression patterns in patients with BCR/ABL-positive and cytogenetically negative ALL with respect to achievement of complete remission and duration of disease-free and overall survival.
OUTLINE: This is a multicenter study.
Total RNA is isolated from stored tissue samples and integrity is verified by reverse transcription-polymerase chain reaction (RT-PCR). cDNA libraries are created from total RNA and gene expression is analyzed via microarray analysis.
Genes of interest are further analyzed by flow cytometry and RT-PCR.
PROJECTED ACCRUAL: A total of 137 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||137 participants|
|Official Title:||Genetic Risk Classes in Adult Acute Lymphocytic Leukemia|
|Actual Study Start Date :||October 26, 2007|
|Actual Primary Completion Date :||July 19, 2012|
|Actual Study Completion Date :||July 19, 2012|
- Genes involved in specific biologic processes or molecular functions that contribute to the mechanisms by which the BCR/ABL tyrosine kinase induces a leukemic phenotype [ Time Frame: 1 month ]
- Comparison of patterns of mRNA expression of BCR/ABL fusion protein in patients with B-lineage acute lymphoblastic leukemia (ALL) vs patients with ALL who lack cytogenetic abnormalities [ Time Frame: 1 month ]
- Shared and differing expression patterns in patients with BCR/ABL-positive and cytogenetically negative ALL with respect to achievement of complete remission and duration of disease-free and overall survival [ Time Frame: 1 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00898261
|Study Chair:||Elisabeth Paietta, PhD||Our Lady of Mercy Medical Center|